Sara Amalie Solheim

Sara Amalie Solheim

Auto-generated profile, based on publicly available information

Sara Amalie Solheim

Science and Research Anti Doping Denmark Brøndby Denmark

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 August 2021 in Drug Testing and Analysis
Verified
Journal Article
Closed access
PDF file
SSSara Amalie Solheim
Sara Amalie Solheim
TRThomas Kamm Ringsted
Thomas Kamm Ringsted
NNNikolai Nordsborg
Nikolai Nordsborg
YDYvette Dehnes
Yvette Dehnes
MLMaren Christin Stillesby Levernæs
Maren Christin Stillesby Levernæs
JMJakob Mørkeberg
Jakob Mørkeberg

17 March 2021 in Drug Testing and Analysis
Verified
Journal Article
Open access
PDF file
SSSara Amalie Solheim
Sara Amalie Solheim
MLMaren Christin Stillesby Levernæs
Maren Christin Stillesby Levernæs
JMJakob Mørkeberg
Jakob Mørkeberg
AJAnders Juul
Anders Juul
EUEmmie N. Upners
Emmie N. Upners
YDYvette Dehnes
Yvette Dehnes
While misuse of testosterone esters is widespread in elite and recreational sports, direct detection of intact testosterone esters in doping control samples is hampered by the rapid hydrolysis by esterases present in the blood. With dried blood spot (DBS) as sample matrix, continued degradation of the esters is avoided due to inactivation of the hydrolase enzymes in dried blood. Here, we have developed the method further for detection of testosterone esters in DBS with focus on robustness and applicability in doping control. To demonstrate the method's feasibility, DBS samples from men receiving two intramuscular injections of Sustanon® 250 (n = 9) or placebo (n = 10) were collected, transported, and stored prior to analysis, to mimic a doping control scenario. The presented nanoLC‐HRMS/MS method appeared reliable and suitable for direct detection of four testosterone esters (testosterone decanoate, isocaproate, phenylpropionate, and propionate) after extraction from DBS. Sustanon® was detected in all subjects for at least 5 days, with detection window up to 14 days for three of the esters. Evaluation of analyte stability showed that while storage at room temperature is tolerated well for a few days, testosterone esters are highly stable (>18 months) in DBS when stored in frozen conditions. Collectively, these findings demonstrate the applicability of DBS sampling in doping control for detection of steroid esters. The fast collection and reduced shipment costs of DBS compared with urine and standard blood samples, respectively, will allow more frequent and/or large‐scale testing to increase detection and deterrence.

1 April 2019 in Medicine & Science in Sports & Exercise
Verified
Journal Article
Closed access
JBJacob Bejder
Jacob Bejder
AAAndreas Breenfeldt Andersen
Andreas Breenfeldt Andersen
SSSara Amalie Solheim
Sara Amalie Solheim
MGMikkel Gybel-Brask
Mikkel Gybel-Brask
NSNiels Henry Secher
Niels Henry Secher
NNNikolai Nordsborg
Nikolai Nordsborg
Purpose: This study tested the hypothesis that autologous blood transfusion (ABT) of ~50% of the red blood cells (RBC) from a standard 450-mL phlebotomy would increase mean power in a cycling time trial. In addition, the study investigated whether further ABT of RBC obtained from another 450-mL phlebotomy would increase repeated cycling sprint ability.Methods: In a randomized, double-blind, placebo-controlled crossover design (3-month wash-out), nine highly trained male subjects donated two 450-mL blood bags each (BT trial) or were sham phlebotomized (PLA trial). Four weeks later, a 650-kcal time trial (n= 7) was performed 3 d before and 2 h after receiving either ~50% (135 mL) of the RBC or a sham transfusion. On the following day, transfusion of RBC (235 mL) from the second donation or sham transfusion was completed. A 4 × 30-s all-out cycling sprint interspersed by 4 min of recovery was performed 6 d before and 3 d after the second ABT (n= 9).Results: The mean power was increased in time trials from before to after transfusion (P< 0.05) in BT (213 ± 35 vs 223 ± 38 W; mean ± SD) but not in PLA (223 ± 42 vs 224 ± 46 W). In contrast, the mean power output across the four 30-s sprint bouts remained similar in BT (639 ± 35 vs 644 ± 26 W) and PLA (638 ± 43 vs 639 ± 25 W).Conclusions: ABT of only ~135 mL of RBC is sufficient to increase mean power in a 650-kcal cycling time trial by ~5% in highly trained men. In contrast, a combined high-volume transfusion of ~135 and ~235 mL of RBC does not alter 4 × 30-s all-out cycling performance interspersed with 4 min of recovery.


8 July 2019 in Sports Medicine - Open
Verified
Journal Article
Open access
PDF file
SSSara Amalie Solheim
Sara Amalie Solheim
JBJacob Bejder
Jacob Bejder
AAAndreas Breenfeldt Andersen
Andreas Breenfeldt Andersen
JMJakob Mørkeberg
Jakob Mørkeberg
NNNikolai Nordsborg
Nikolai Nordsborg
This review critically evaluates the magnitude of performance enhancement that can be expected from various autologous blood transfusion (ABT) procedures and the underlying physiological mechanisms. The review is based on a systematic search, and it was reported that 4 of 28 studies can be considered of very high quality, i.e. placebo-controlled, double-blind crossover studies. However, both high-quality studies and other studies have generally reported performance-enhancing effects of ABT on exercise intensities ranging from ~70 to 100% of absolute peak oxygen uptake (VO2peak) with durations of 5–45 min, and the effect was also seen in well-trained athletes. A linear relationship exists between ABT volume and change in VO2peak. The likely correlation between ABT volume and endurance performance was not evident in the few available studies, but reinfusion of as little as 135 mL packed red blood cells has been shown to increase time trial performance. Red blood cell reinfusion increases endurance performance by elevating arterial oxygen content (CaO2). The increased CaO2 is accompanied by reduced lactate concentrations at submaximal intensities as well as increased VO2peak. Both effects improve endurance performance. Apparently, the magnitude of change in haemoglobin concentration ([Hb]) explains the increase in VO2peak associated with ABT because blood volume and maximal cardiac output have remained constant in the majority of ABT studies. Thus, the arterial-venous O2 difference during exercise must be increased after reinfusion, which is supported by experimental evidence. Additionally, it remains a possibility that ABT can enhance repeated sprint performance, but studies on this topic are lacking. The only available study did not reveal a performance-enhancing effect of reinfusion on 4 × 30 s sprinting. The reviewed studies are of importance for both the physiological understanding of how ABT interacts with exercise capacity and in relation to anti-doping efforts. From an anti-doping perspective, the literature review demonstrates the need for methods to detect even small ABT volumes.

4 June 2020 in Drug Testing and Analysis
Verified
Journal Article
Closed access
PDF file
SSSara Amalie Solheim
Sara Amalie Solheim
SJSøren Jessen
Søren Jessen
JMJakob Mørkeberg
Jakob Mørkeberg
MTMario Thevis
Mario Thevis
YDYvette Dehnes
Yvette Dehnes
NNNikolai Nordsborg
Nikolai Nordsborg